Evidence map›Paper›PMID 39615166›Full record

ArticleBiomedicine & pharmacotherapy = Biomedecine & pharmacotherapie2024

Hydroxyurea inhibits proliferation and stimulates apoptosis through inducible nitric oxide synthase in erythroid cells.

Teodora Dragojević, Emilija Živković, Miloš Diklić, Olivera Mitrović Ajtić, Miloš Lazarević, Tijana Subotički, Dragoslava Đikić, Juan F Santibanez, Dejan Milenković, Jasmina Dimitrić Marković and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Teodora DragojevićDepartment of molecular oncology, Institute for Medical Research, National Institute of the Republic of Serbia, University of Belgrade, Serbia.
Emilija ŽivkovićDepartment of molecular oncology, Institute for Medical Research, National Institute of the Republic of Serbia, University of Belgrade, Serbia.
Miloš DiklićDepartment of molecular oncology, Institute for Medical Research, National Institute of the Republic of Serbia, University of Belgrade, Serbia.
Olivera Mitrović AjtićDepartment of molecular oncology, Institute for Medical Research, National Institute of the Republic of Serbia, University of Belgrade, Serbia.
Miloš LazarevićDepartment for Human Genetics, Implantology Research Center, Faculty of Dentistry, University of Belgrade, Serbia.
Tijana SubotičkiDepartment of molecular oncology, Institute for Medical Research, National Institute of the Republic of Serbia, University of Belgrade, Serbia.
Dragoslava ĐikićDepartment of molecular oncology, Institute for Medical Research, National Institute of the Republic of Serbia, University of Belgrade, Serbia.
Juan F SantibanezDepartment of molecular oncology, Institute for Medical Research, National Institute of the Republic of Serbia, University of Belgrade, Serbia.
Dejan MilenkovićInstitute for Information Technologies, University of Kragujevac, Serbia.
Jasmina Dimitrić MarkovićFaculty of Physical Chemistry, University of Belgrade, Serbia.
Constance T NoguchiMolecular Medicine Branch, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, Bethesda, MD, USA.
Alan N SchechterMolecular Medicine Branch, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, Bethesda, MD, USA.
Vladan P ČokićDepartment of molecular oncology, Institute for Medical Research, National Institute of the Republic of Serbia, University of Belgrade, Serbia.
Milica VukotićDepartment of molecular oncology, Institute for Medical Research, National Institute of the Republic of Serbia, University of Belgrade, Serbia. Electronic address: milica.tosic@imi.bg.ac.rs.

Funding

TRANS-ACTING FACTOR(S) CONTROLLING GLOBIN GENE EXPRESSION IN K562 CELLS &MICEZ01DK025016 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI SCHECHTER, ALAN N. · 1986 to 2008
$277k
Intramural NIH HHS Z01 DK025016
6 · The paper itself

Abstract

Hydroxyurea (hydroxycarbamide, HU) arrests cells in the S-phase by inhibiting ribonucleotide reductase and DNA synthesis, significantly contributing to the release of nitric oxide (NO). We investigated the involvement of inducible NO synthase (NOS2) in the cytostatic effect of HU using in vitro shRNA-induced knockdown of the NOS2 transcript (NOS2

Indexed as

ApoptosisCell ProliferationErythroid CellsHydroxyureaMice, KnockoutNitric Oxide Synthase Type IIAnimalsCell Line, TumorHumansMiceMice, Inbred C57BLMolecular Docking SimulationNF-kappa BNitric OxideSignal TransductionHydroxyureaNF-kappa BNitric OxideNitric Oxide Synthase Type IINOS2 protein, humanApoptosisErythroid cellsHydroxyureaInducible nitric oxide synthaseProliferation

Identifiers

PMID39615166
PMCPMC12182844

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.